Breakthrough Treatment for Oral Lichen Planus

Oral lichen planus (OLP) is a chronic, T-cell–mediated inflammatory disorder affecting the oral mucosa. Characterized by bilateral, symmetrical white reticular or plaque-like lesions—often accompanied by erythema, erosions, or ulcerations—OLP can cause significant pain, burning sensations, and functional impairment, particularly when erosive or atrophic subtypes are present.

There is no universally approved “targeted” or “disease-modifying” pharmacotherapy for OLP. Current management focuses on symptom control and suppression of local inflammation. First-line treatment remains topical corticosteroids—such as clobetasol propionate 0.05% ointment or fluocinonide 0.05% gel—applied directly to affected areas two to three times daily. These agents effectively reduce lymphocytic infiltration and epithelial apoptosis, leading to clinical improvement in approximately 60–70% of patients with mild-to-moderate disease.

For refractory or widespread erosive OLP, second-line options include topical calcineurin inhibitors (e.g., tacrolimus 0.1% ointment or pimecrolimus 1% cream), which modulate T-cell activation without inducing mucosal atrophy. Systemic corticosteroids are reserved for severe, unresponsive cases due to their adverse effect profile, and should be used at the lowest effective dose for the shortest duration possible.

Emerging evidence supports adjunctive use of photobiomodulation therapy and low-level laser therapy for pain reduction and epithelial healing. While several investigational agents—including JAK inhibitors and anti-IL-23 biologics—are under early-phase evaluation, none have yet received regulatory approval for OLP. Rigorous, multicenter randomized controlled trials remain needed to establish efficacy and long-term safety.

Given its chronic, relapsing nature, OLP requires ongoing clinical monitoring—not only for therapeutic response but also for malignant transformation. Although the overall risk of oral squamous cell carcinoma is low (estimated at 0.5–2.0% over 10 years), patients with persistent erosive lesions warrant regular biopsy of non-healing or suspicious areas. Interdisciplinary care involving oral medicine specialists, dermatologists, and oral pathologists optimizes both diagnosis and longitudinal management.